Detalhe da pesquisa
1.
mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease.
Mol Cell
; 71(5): 675-688.e6, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30193095
2.
HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy.
PLoS Genet
; 11(3): e1005021, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25748626
3.
Dysfunction of the CNS-heart axis in mouse models of Huntington's disease.
PLoS Genet
; 10(8): e1004550, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25101683
4.
HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.
PLoS Biol
; 11(11): e1001717, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24302884
5.
Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice.
Sci Rep
; 7(1): 14275, 2017 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079832
6.
The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model.
PLoS One
; 9(9): e108961, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25268775
7.
HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo.
PLoS One
; 8(11): e80849, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24278330
8.
SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.
PLoS One
; 6(11): e27746, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22140466